Lutetium (lu177) lilotomab satetraxetan is under clinical development by Nordic Nanovector and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Lutetium (lu177) lilotomab satetraxetan’s likelihood of approval (LoA) and phase transition for B-Cell Chronic Lymphocytic Leukemia took place on 29 Sep 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Lutetium (lu177) lilotomab satetraxetan Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Lutetium (lu177) lilotomab satetraxetan overview

Betalutin (177Lu-HH1) is under development for the treatment of non-Hodgkin B-cell lymphoma of subtypes follicular grade I-IIIA, marginal zone, small lymphocytic, lymphoplasmacytic, mantle cell lymphoma and other non-hodkin's lymphomas in combination with CD20. It is administered as an intravenous and parenteral route. The drug candidate is a monoclonal antibody (HH1) conjugated with a radionuclide Lutetium-177 (177Lu). It is a radioimmunotherapeutic developed using nanovector targeting technology. Betalutin targets CD37 antigen.

It was under development for the treatment of diffuse large B-cell lymphoma.

Nordic Nanovector overview

Nordic Nanovector, formerly Nordic Nanovector is a developer and commercializer of antibody radionuclide conjugates for the treatment of hematological cancers. The company’s lead product candidate includes Betalutin, an antibody radionuclide conjugate developed for the treatment of non-Hodgkin Lymphoma, a life-threatening blood cancer. Its Betalutin consists of tumor-specific antibody HH1, which targets CD37 antigen on the surface of NHL cells. Nordic Nanovector develops products for the treatment of multiple cancer indications by utilizing innovative therapy programs and patented technologies. The company evaluates chimeric anti-CD37 antibodies with different payloads for the treatment of both types of leukemia. It operates in Norway, Switzerland and the UK. Nordic Nanovector is headquartered in Oslo, Norway

Quick View Lutetium (lu177) lilotomab satetraxetan LOA Data

Report Segments
  • Innovator
Drug Name
  • Lutetium (lu177) lilotomab satetraxetan
Administration Pathway
  • Intravenous
  • Parenteral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.